Nicholson Nur
Insider CIK 1827317 · APLS Chief Technical Officer · KLRA Chief Technology Officer
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| KLRA Kailera Therapeutics, Inc. | A Award deriv | 2026-09-07 | 2026-09-09 | 220,000 | — | $0 | 220,000 | SEC↗ |
| KLRA Kailera Therapeutics, Inc. | A Award deriv | 2026-09-07 | 2026-09-09 | 220,000 | — | $0 | 220,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 50,974 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 35,472 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 45,000 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 28,367 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 115,281 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer deriv | 2026-05-14 | 2026-05-14 | 82,500 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 24,284 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 27,320 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 9,754 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 5,645 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 41,250 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-05-14 | 2026-05-14 | 41,250 | — | $0 | 41,250 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 45,220 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-05-14 | 2026-05-14 | 24,284 | — | $0 | 24,284 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 45,220 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-05-14 | 2026-05-14 | 45,220 | — | $0 | 45,220 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | D To issuer | 2026-05-14 | 2026-05-14 | 22,610 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-05-14 | 2026-05-14 | 22,610 | — | $0 | 22,610 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | U Tender | 2026-05-14 | 2026-05-14 | 116,338 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2026-01-28 | 2026-01-30 | 45,220 | — | $0 | 116,338 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2026-01-22 | 2026-01-23 | 7,725 | $21.77 | $168.2K | 71,118 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2026-01-20 | 2026-01-21 | 2,203 | $19.79 | $43.6K | 78,843 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2026-01-13 | 2026-01-15 | 2,618 | $22.19 | $58.1K | 81,046 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2025-06-09 | 2025-06-11 | 82,500 | $19.39 | $1.60M | 82,500 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-01-29 | 2025-01-30 | 825 | $29.52 | $24.4K | 83,664 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-01-22 | 2025-01-23 | 3,948 | $30.43 | $120.1K | 84,489 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2025-01-21 | 2025-01-21 | 36,426 | — | $0 | 88,437 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-01-17 | 2025-01-21 | 2,145 | $29.96 | $64.3K | 52,011 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2025-01-13 | 2025-01-14 | 2,632 | $28.70 | $75.5K | 54,156 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-03-13 | 2024-03-14 | 7,768 | $57.31 | $445.2K | 59,739 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-03-13 | 2024-03-14 | 3,452 | $58.13 | $200.7K | 56,287 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-01-29 | 2024-01-31 | 835 | $64.14 | $53.6K | 67,507 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-01-22 | 2024-01-23 | 2,593 | $65.00 | $168.5K | 68,342 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2024-01-16 | 2024-01-17 | 28,367 | $66.30 | $1.88M | 28,367 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2024-01-16 | 2024-01-17 | 19,508 | — | $0 | 72,792 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2024-01-16 | 2024-01-17 | 1,857 | $66.81 | $124.1K | 70,935 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise deriv | 2023-09-18 | 2023-09-19 | 9,719 | — | $0 | 115,281 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | M Exercise | 2023-09-18 | 2023-09-19 | 9,719 | $29.76 | $289.2K | 73,634 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-09-18 | 2023-09-19 | 10,631 | $46.15 | $490.6K | 53,284 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | S Sale | 2023-09-18 | 2023-09-19 | 9,719 | $42.21 | $410.2K | 63,915 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2023-02-21 | 2023-02-22 | 14,023 | — | $0 | 14,023 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2023-02-21 | 2023-02-22 | 9,886 | — | $0 | 64,328 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2023-02-21 | 2023-02-22 | 825 | $58.50 | $48.3K | 63,503 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2023-01-27 | 2023-01-30 | 551 | $52.77 | $29.1K | 54,442 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2023-01-20 | 2023-01-24 | 2,034 | $52.05 | $105.9K | 54,993 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2023-01-12 | 2023-01-17 | 35,472 | $52.66 | $1.87M | 35,472 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2023-01-12 | 2023-01-17 | 22,580 | — | $0 | 57,027 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | J Other deriv | 2022-04-25 | 2023-01-17 | 11,250 | — | $0 | 0 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | J Other | 2022-04-25 | 2023-01-17 | 1,875 | — | $0 | 33,680 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | F Tax w/h | 2022-01-28 | 2022-02-01 | 650 | $38.59 | $25.1K | 35,555 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2022-01-21 | 2022-01-25 | 36,951 | — | $0 | 36,951 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2022-01-21 | 2022-01-25 | 26,051 | — | $0 | 36,205 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2021-01-28 | 2021-02-01 | 45,000 | — | $0 | 45,000 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award deriv | 2021-01-28 | 2021-02-01 | 11,250 | — | $0 | 11,250 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2021-01-28 | 2021-02-01 | 7,500 | — | $0 | 7,500 | SEC↗ |
| APLS Apellis Pharmaceuticals, I | A Award | 2021-01-28 | 2021-02-01 | 1,875 | — | $0 | 9,375 | SEC↗ |